Next Generation Researchers in Cancer Cachexia

Speakers:
Andrew D’Lugos, PhD – University of Florida, USA
The role of complement in pancreatic cancer cachexia

Erin Talbert, PhD – University of Iowa, USA
Plasma ceramides as a sexually dimorphic biomarker of pancreatic cancer-induced cachexia

Brian Hain, PhD – The Pennsylvania State University College of Medicine, USA
Loss of REDD1 prevents chemotherapy-induced muscle atrophy and weakness in mice

Estefanía Simoes Fernández – University of São Paulo, Brazil
Neuronal morphology and neuroglia compromised in cancer cachexia: a post-mortem neuropathological study

Joshua Huot, PhD – Indiana University School of Medicine, USA
ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia

Brandon VanderVeen, PhD – University of South Carolina, School of Medicine, USA
The effects of chemotherapy on skeletal muscle immune cell infiltration and activation

The speaker's disclosure of Conflict of Interest is available on the conference website.


Learning Objectives:
At the end of this presentation, the participant will be able to:
1 - Recognize early phase career clinicians and scientists who have committed their clinical practice and research labs to cancer cachexia.
2 - Realize an opportunity for junior investigators to discuss their clinical trial, translational, and basic science research.

Chairs:
Rishi Jain, MD – Fox Chase Cancer Center, USA
Cynthia Stretch, PhD – University of Calgary, Canada
 

Please rate from low (1) to high (5).

Question Title

* 1. Your name and email (this information will not be shared with anyone)

Question Title

* 2. Please rate the quality of the session on a scale of 1 (strongly disagree) to 5 (strongly agree).

  1 - Strongly Disagree 2 - Disagree 3 - Neutral 4 - Agree 5 - Strongly Agree
Met the stated learning objectives
Enhanced my knowledge
Satisfied my expectations
Conveyed information that applied to my practice
Allocated at least 25% of the time for interaction
Was free from commercial bias

Question Title

* 3. If you perceived any sources of commercial bias, please describe:

(ranked the previous question a 1 or 2)

Question Title

* 4. What did you learn or how will this educational session impact your practice?

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity?

Question Title

* 6. Please rate the presenter, Dr. Andrew D'Lugos:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 7. Please rate the presenter, Dr. Erin Talbert:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 8. Please rate the presenter, Dr. Brian Hain:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 9. Please rate the presenter, Dr. Estefania Simoes Fernández:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 10. Please rate the presenter, Dr. Joshua Huot:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 11. Please rate the presenter, Dr. Brandon VanderVeen:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Knowledge
Presentation Skills
Topic Relevance

Question Title

* 12. Please rate the overall session:

  1 - Bad 2 - Not Bad 3 - Good 4 - Very Good 5 - Extremely Good
Next Generation Researchers in Cancer Cachexia

Question Title

* 13. Any additional comments?

T